Pharmasset (VRUS +6.4%) shares rise on renewed hopes for a hepatitis C drug after announcing a...


Pharmasset (VRUS +6.4%) shares rise on renewed hopes for a hepatitis C drug after announcing a collaboration with Johnson & Johnson (JNJ -0.2%) to test their drugs together in a mid-stage human trial. Shares of competitor Vertex (VRTX -3.4%) slip, but have surged 40%-plus this year; also, Canaccord initiates coverage with a tepid Hold.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs